| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | D2G ONCOLOGY, INC. | 353 LOWELL AVE | PALO ALTO | CA | 94301-3812 | SANTA CLARA | USA | R44CA250672 | Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform | 000 | 2 | NIH | 10/20/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $865,070 ) |
| | 2021 | 2021 | D2G ONCOLOGY, INC. | 353 LOWELL AVE | PALO ALTO | CA | 94301-3812 | SANTA CLARA | USA | R44CA250672 | Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform | 000 | 2 | NIH | 8/26/2021 | $865,070 |
|
| Issue Date FY: 2020 ( Subtotal = $1,134,487 ) |
| | 2020 | 2020 | D2G ONCOLOGY, INC. | 353 LOWELL AVE | PALO ALTO | CA | 94301-3812 | SANTA CLARA | USA | R44CA250672 | Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform | 000 | 1 | NIH | 9/8/2020 | $1,134,487 |
|
|
